

"n", where "n" must be equal to a nucleotide or a modified nucleotide. The Specification defines the fluorescent nucleotide analogs as the compounds listed where "n" was defined in the Sequence Listing. Thus, "n" is equal to a modified nucleotide.

To specifically detail the locations in the Specification where these definitions occur, reference should be made to:

1) Table 2 on page 39, where the sequences containing an "F" symbol occur, and the columns labeled "w/6MAP" and "w/DMAP" indicated which analogs are used.

2) The paragraph beginning on page 39, line 10, describing Table 2, where it states "in each row, F denotes the position of the probe within the sequence." Oligonucleotides containing 6MAP are number from 21 to 28 and those containing DMAP are numbered from 31 to 38.

3) Table 1 on page 38, following line 15, where "6MAP" and "DMAP" are defined as "compound 11" and "compound 12", respectively.

4) Example 4 A, page 33, lines 23-25, which gives the chemical name for compound 11, and Example 4B, page 34, lines 9-11, where the chemical name for compound 12 are described.

The Sequence Listing defines each "n", for the "modified base", in the "F" positions from each of the sequences found in Table 2 exactly as defined on pages 33 and 34. Therefore, Applicant respectfully requests that the "Notification of Defective Response" be withdrawn.

HAWKINS et al.
Application No.: 09/786,666
Page 3

CONCLUSION

In view of the foregoing, Applicant believes the Sequence Listing now pending in this Application is proper. A first Action on the merits at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
SLW
SF 1274311 v1